1,282 results on '"Gerds, A. T."'
Search Results
2. Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.
3. How I treat anemia in myelofibrosis
4. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis
5. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL
6. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
7. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
8. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
9. A Review of Real-World Experience With Ruxolitinib for Myelofibrosis
10. Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib
11. Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel
12. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
13. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
14. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
15. Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
16. Consensus recommendations on peripheral blood smear review: defining curricular standards and fellow competency
17. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
18. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML
19. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
20. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
21. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib
22. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
23. Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study
24. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia
25. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
26. Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome
27. The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
28. NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024
29. Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era
30. A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
31. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia
32. Unmet Need in Essential Thrombocythemia and Polycythemia Vera
33. Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation
34. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
35. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase
36. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS
37. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera
38. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
39. Survival following allogeneic transplant in patients with myelofibrosis
40. Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study
41. Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation
42. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
43. Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span
44. Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation
45. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study
46. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib
47. Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia?
48. Reduced Intensity Versus Myeloablative Allogeneic Hematopoietic Cell Transplant for Myelofibrosis: A Single Institution Experience
49. Reduced Intensity Versus Myeloablative Allogeneic Hematopoietic Cell Transplant for Chronic Myelomonocytic Leukemia: A Single Institution Experience
50. Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.